Loading
C4 Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Koppikar Utpal, was filed 10 Feb 2023.
C4 Therapeutics, Inc.: what insiders have been doing
Every trade that managers of C4 Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 10 insiders have disclosed 47 filings since 22 October 2025.
All open-market trades in the period are sales: 1 sale worth €19k, by 1 insider, with no purchase on record. Reyno Leonard filed the largest sale, €19k, on 16 January 2026.
Compared with its exchange (3,171 companies, median 24 filings), a count of 47 filings is above the norm. Our records for C4 Therapeutics, Inc. go back to 2020, with 5 purchases and 52 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 35.9 m USD and net income at -105.0 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
326
Thresholds
n/a
Buy Volume
€295,068
5 ops. · all time
Sell Volume
€14M
52 ops. · all time
Who traded when
BuySaleScott N. Boyle2 sales
Leonard Reyno1 sale
Since the insiders bought
- +19.2%Entry US$5.67 · Close at T+365 US$6.76
- -64.8%Entry US$9.35 · Close at T+365 US$3.29
- +79.8%Entry US$24.60 · Close at T+365 US$44.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate C4 Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$12.86.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.16
Analyst consensus
7 analystsStrong buy
US$7.00Target US$12.86(+307%)US$30.00
Income statement
RevenueUS$35.9M
EBITDA-US$102.5M-285% margin
Net income-US$105M-289.4% margin
Valuation
PER (forward)-3.3x
P/Book1.6x
Beta3.08
Balance sheet & cash
Market capUS$388.8M
Total debtUS$60M
Free Cash Flow-US$99.3M
Debt / Equity23%
Profitability & ownership
ROE-48.1%
ROA-19.3%
% insiders0.8%
% institutions104.2%
Last declaration on 2 October 2026
Declarations326 total
3,662 shares@ US$3.140.0029% mcap5.1% of flowCommon StockSEC:0001470831-26-000925:0
4,618 shares@ US$3.140.0036% mcap6.6% of flowCommon StockSEC:0001470831-26-000924:0
6,250 shares0Common StockSEC:0001470831-26-000895:0
2,775 shares@ US$3.390.0027% mcap14.6% of flowCommon StockSEC:0001470831-26-000895:1
4,139 shares@ US$4.25340.0046% mcap11.3% of flowCommonSEC144:0001950047-26-008193
15,000 shares@ US$4.07150.016% mcap39.3% of flowCommonSEC144:0001950047-26-008065
19,519 shares@ US$3.92850.020% mcap49.3% of flowCommonSEC144:0001950047-26-008039
15,325 shares0Common StockSEC:0001470831-26-000705:0
7,397 shares@ US$4.060.0079% mcap30.3% of flowCommon StockSEC:0001470831-26-000705:1
2,650 sharesCommon StockSEC:0001470831-26-000688:0
1,070 shares@ US$2.110.0004% mcap1.0% of flowCommon StockSEC:0001470831-26-000504:0
4,259 shares@ US$2.705.3% of flowCommon StockSEC:0001470831-26-000346:0
5,370 shares@ US$2.706.9% of flowCommon StockSEC:0001470831-26-000345:0
81,725 shares0Common StockSEC:0001470831-26-000177:1
20,400 shares0Common StockSEC:0001470831-26-000177:3
30,950 shares0Common StockSEC:0001470831-26-000176:1
5,000 shares0Common StockSEC:0001470831-26-000178:1
20,950 shares0Common StockSEC:0001470831-26-000178:3
3,750 shares0Common StockSEC:0001470831-26-000175:1
30,950 shares0Common StockSEC:0001470831-26-000175:3
7,050 shares0Common StockSEC:0001470831-26-000179:1
5,000 shares0Common StockSEC:0001470831-26-000180:1
20,950 shares0Common StockSEC:0001470831-26-000180:3
9,420 shares0Common StockSEC:0001470831-26-000174:1
39,154 shares@ US$1.8916.4% of flowCommon StockSEC:0001470831-26-000177:2
25 of 326 declarations
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a US-listed biopharmaceutical company headquartered in Watertown, Massachusetts, United States, and founded in 2015. For investors, it fits the profile of a clinical-stage biotech focused on a differentiated scientific platform rather than a commercialized product portfolio. The company’s core mission is to harness targeted protein degradation (TPD), an approach intended to eliminate disease-causing proteins instead of merely inhibiting them. ([c4therapeutics.com](https://c4therapeutics.com/our-company/?utm_source=openai))
C4 Therapeutics’ proprietary TORPEDO® platform is designed to discover and optimize small-molecule degraders efficiently, leveraging the body’s natural protein recycling machinery. Management presents the platform as a potential way to address hard-to-drug targets, overcome resistance mechanisms and create oral medicines with high potency and specificity. In competitive terms, C4T operates in the emerging protein-degradation space, where scientific credibility, translational execution and partnership quality matter as much as headline clinical assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1662579/000156459022006499/cccc-10k_20211231.htm?utm_source=openai))
Read moreShow less
The company’s most important internal programs are concentrated in oncology. Cemsidomide is an IKZF1/3 degrader being advanced for relapsed/refractory multiple myeloma, including later-stage development activity in 2026. CFT1946 targets BRAF V600 mutations in solid tumors, while CFT8919 is an EGFR L858R degrader being developed for non-small-cell lung cancer, with initial work conducted in Greater China through a partner. Beyond these lead programs, C4 Therapeutics continues to explore additional discovery efforts in inflammation, neuroinflammation and neurodegeneration, which broadens the platform narrative beyond oncology over time. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Geographically, the company remains anchored in the United States, with research and corporate operations in Watertown, Massachusetts, while leveraging a network of global collaborations. Strategic partnerships with Roche, Biogen, Merck KGaA and Pfizer show that C4T uses collaboration both to validate its science and to help finance development. That model can reduce some standalone development burden, but it also means future value creation depends heavily on partner execution and milestone delivery. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-transformation-strategic-collaboration/?utm_source=openai))
Recent developments reinforce the investment case as a catalyst-driven biotech story. In 2025–2026, C4 Therapeutics reported that cemsidomide advanced into Phase 2 MOMENTUM in fourth-line-or-later multiple myeloma, with a combination study with elranatamab expected to begin in Q2 2026. The company also highlighted that a second degrader designed and delivered to Biogen entered clinical development for autoimmune disease, and its year-end 2025 update disclosed cash, cash equivalents and marketable securities of $297.1 million, supporting runway into the end of 2028. ([ir.c4therapeutics.com](https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
